tiprankstipranks
Futura Medical PLC (GB:FUM)
LSE:FUM

Futura Medical (FUM) Share Price & Analysis

15 Followers

FUM Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range23.28p - 67.00p
Previous Close35.45p
Volume246.68K
Average Volume (3M)894.34K
Market Cap
£106.86M
Enterprise Value102.84M
Total Cash (Recent Filing)£4.03M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)-17.7
Beta0.59
Sep 11, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding300,712,293
10 Day Avg. Volume402,626
30 Day Avg. Volume894,341
Standard Deviation0.32
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)13.31
Price to Sales (P/S)2383.18
Price to Cash Flow (P/CF)-90.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside252.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

1.41%0.00%0.00%98.59%
0.00% Other Institutional Investors
98.59% Public Companies and
Individual Investors

FUM FAQ

What was Futura Medical PLC’s price range in the past 12 months?
Futura Medical PLC lowest share price was 23.28p and its highest was 67.00p in the past 12 months.
    What is Futura Medical PLC’s market cap?
    Currently, no data Available
    When is Futura Medical PLC’s upcoming earnings report date?
    Futura Medical PLC’s upcoming earnings report date is Sep 11, 2024 which is in 132 days.
      How were Futura Medical PLC’s earnings last quarter?
      Futura Medical PLC released its earnings results on Apr 10, 2024. The company reported -0.016p earnings per share for the quarter, missing the consensus estimate of N/A by -0.016p.
        Is Futura Medical PLC overvalued?
        According to Wall Street analysts Futura Medical PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Futura Medical PLC pay dividends?
          Futura Medical PLC does not currently pay dividends.
          What is Futura Medical PLC’s EPS estimate?
          Futura Medical PLC’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Futura Medical PLC have?
          Futura Medical PLC has 301,449,460 shares outstanding.
            What happened to Futura Medical PLC’s price movement after its last earnings report?
            Futura Medical PLC reported an EPS of -0.016p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.551%.
              Which hedge fund is a major shareholder of Futura Medical PLC?
              Currently, no hedge funds are holding shares in GB:FUM
              ---

              Company Description

              Futura Medical PLC

              Futura Medical PLC is a drug manufacturer based in the United Kingdom. It lays primary focus exclusively on topically applied pharmaceutical drugs and medical devices which are developed using a highly efficient and proprietary transdermal delivery technology, DermaSys. DermaSys is a versatile technology that can be customized to suit the specific active compound being used and the therapeutic indication. Futura's products are used mainly for the treatment of erectile dysfunction and pain relief.
              ---

              FUM Stock 12 Months Forecast

              Average Price Target

              125.00p
              ▲(252.61% Upside)
              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"26p","51":"51p","76":"76p","101":"101p","126":"126p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">125.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">125.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">125.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,51,76,101,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.2,43.03076923076923,49.861538461538466,56.69230769230769,63.52307692307693,70.35384615384615,77.18461538461538,84.01538461538462,90.84615384615384,97.67692307692307,104.50769230769231,111.33846153846154,118.16923076923077,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.2,43.03076923076923,49.861538461538466,56.69230769230769,63.52307692307693,70.35384615384615,77.18461538461538,84.01538461538462,90.84615384615384,97.67692307692307,104.50769230769231,111.33846153846154,118.16923076923077,{"y":125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.2,43.03076923076923,49.861538461538466,56.69230769230769,63.52307692307693,70.35384615384615,77.18461538461538,84.01538461538462,90.84615384615384,97.67692307692307,104.50769230769231,111.33846153846154,118.16923076923077,{"y":125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":51.6,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":41.2,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":60,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":54.8,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":52,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43.6,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":28.55,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":29,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":41.8,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":36.2,"date":1712880000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              C4X Discovery Holdings
              OptiBiotix Health
              Hikma Pharmaceuticals
              EKF Diagnostics Holdings

              Best Analysts Covering FUM

              1 Year
              James OrsborneStifel Nicolaus
              1 Year Success Rate
              0/1 ratings generated profit
              0%
              1 Year Average Return
              -4.10%
              initiated a buy rating 23 days ago
              Copying James Orsborne's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -4.10% per trade.
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis